Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial
Author:
Funder
Canadian Institutes of Health Research
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/29/4/1056/25082449/mdx730.pdf
Reference26 articles.
1. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer;Luen;Pathology,2017
2. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013;Goldhirsch;Ann Oncol,2013
3. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007
4. Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting;García-Teijido;Clin Med Insights Oncol,2016
5. Anti-CD73 immunotherapy: a viable way to reprogram the tumor microenvironment;Antonioli;Oncoimmunology,2016
Cited by 137 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. miR-30b-5p targets CD73 and inhibits gastric cancer migration and invasion via PTEN/AKT/GSK3β/mTOR pathway;2024-01-25
2. CD73 contributes to the pathogenesis of fusion-negative rhabdomyosarcoma through the purinergic signaling pathway;Proceedings of the National Academy of Sciences;2024-01-16
3. NUDT21 interacts with NDUFS2 to activate the PI3K/AKT pathway and promotes pancreatic cancer pathogenesis;Journal of Cancer Research and Clinical Oncology;2024-01-09
4. Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer;Cancers;2023-12-04
5. Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial;Nature Communications;2023-11-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3